Bouchard 1998.
Methods | Allocation: randomised (no further description). Blindness: none, open label. Duration: 2 years. Consent: not stated. Setting: need trial for update. | |
Participants | Diagnosis: schizophrenia (PANSS score 60‐120). N=184. Age: not stated. Sex: not stated. History: 81% outpatients. | |
Interventions | 1. Risperidone: mean dose 5.5 mg/day. N=93. 2. Classical neuroleptics: mean dose 1mg/day chlorpromazine equivalents. N=91. | |
Outcomes | Clinical improvement: 20% reduction in PANSS.
Leaving the study early. Unable to use ‐ Global effect: CGI score (no data). Subjective tolerance: ESRS Part 1 (insufficient data). Movement disorders: ESRS Part 2 (insufficient data). |
|
Notes | Ongoing study ‐ 12 month data only. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |